LONDON – The chief executive of the Swiss pharmaceutical giant Novartis on Wednesday outlined how policy makers and the health industry can learn from the coronavirus crisis to improve pandemic preparedness.
“Pandemics have been with us for hundreds of centuries. If you go back to recorded history, it’s probably on the order of 15 pandemics in the last 200 to 300 years. And, so pandemics temporarily happen, and maybe they should also happen in the future, ”said Novartis CEO Dr. Vas Narasimhan Julianna Tatelbaum in the virtual The CNBC Evolve Global Summit.
“We know what the solutions are-it’s hard to keep investing over time. We need a world-famous company to know exactly when viruses will move from animal populations. to human populations, and we need a policy framework for that information to be shared very quickly, ”he said.
Narasimhan said physical fitness systems require “warm preparedness” such as stock-tile protective-gear and premature manufacturing capabilities. It is also important to maintain stock levels of critical products to help patient care and continue to invest in therapeutics, vaccines and diagnostics, he added.
“We know the answers and we know what needs to happen. The hard thing, I think, can be four [or] five years from now. Often what happens is the attention shifts away from pandemic preparedness, investment decreases and then the level of sensitivity increases, ”Narasimhan said.
A personal protective equipment (PPE) official led the crowd as how many people will receive the Sinopharm Covid-19 coronavirus vaccine in Phnom Penh on May 31, 2021, as part of the government’s campaign to stop the increasing case of the virus.
TANG CHHIN SOTHY | The AFP | Getty Images
“I’m optimistic at this time. I think this pandemic has really become a wake-up call. I also think we have better technology than ever before from a therapeutics and diagnostics perspective, so hope for next pandemic even better. “
Narasimhan said the topic of future pandemic preparedness was discussed by health ministers and other biopharmaceutical executives at the G-7 health minister meeting last month.
The Basel-based company has seen efforts to figure out that there are already drugs to fight the coronavirus pandemic short-lived to date. Novartis announced on December 14 that a later phase of the clinical trial of ruxolitinib in addition to the standard of care therapy did not show a statistically significant reduction in severe complications of Covid-19, including death and admission to the intensive care unit .
The company used to be SAYS The later phase of trials of the anti-inflammatory drug canakinumab failed to help Covid patients.
Just now, Novartis SAYS that alongside Swiss drugmaker Molecular Partners it will begin clinical trials for an investigative drug they are developing to treat Covid.
The clinical trial program, aimed at “Empathy,” is designed to evaluate the safety and efficacy of ensovibep in patients with early Covid infection. The purpose is to prevent worsening of symptoms and hospitalization.
The first phase of the study will enroll 400 patients to determine a dose with the most safety before the second later phase of the trial passes with an additional 1,700 patients. Results are expected in the first half of next year.
In the week to June 15, the count of new cases and deaths in Covid continues to decline, with more than 2.6 million cases and 72,000 deaths reported, according to data compiled by the World Health Organization.
It marked the lowest weekly incidence of cases since February, with weekly cases decreasing in all WHO regions except the Africa region compared to the previous week. The number of new deaths last week fell in all regions expecting Africa and south-east Asia.
To date, more than 176.6 million cases of Covid-19 have been reported worldwide, with 3.82 million deaths, according to Johns Hopkins University data.